Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil

American Journal of Health-System Pharmacy

Volumn 57, Issue 5, 2000, Pages 461-464

  Bermingham, Roger P ^a   Whitsitt, Todd B ^b   Smart, Martin L ^c   Nowak, Diane P ^e   Scalley, Robert D ^d,e  

^a Fort Collins Family Medicine Residency   (United States)

^b Heart and Vascular Clinic of Northern Colorado   (United States)

^c Yuma Clinic   (United States)

^d UNIVERSITY OF WYOMING   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ASCORBIC ACID; ATENOLOL; CERIVASTATIN; COLESTIPOL; CREATINE KINASE; CREATININE; GEMFIBROZIL; HYDROCHLOROTHIAZIDE; IBUPROFEN; LISINOPRIL; MYOGLOBIN; PARACETAMOL; PIPERAZINE ESTRONE SULFATE; VERAPAMIL;

ADULT; ALKALINIZATION; ARTICLE; CASE REPORT; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MUSCLE WEAKNESS; MYALGIA; PRIORITY JOURNAL; REHYDRATION; RHABDOMYOLYSIS; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT PLANNING;

EID: 0034161582     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.5.461     Document Type: Article

References (27)

1. Witzzum JL. Drugs used in the treatment of hyperlipoproteinemias. In: Hardman JG, Limbird LE, Molinoff PB et al., eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996:884-8.
2. Bischoff H, Heller AH. Preclinical and clinical pharmacology of cerivastatin. Am J Cardiol. 1998; 82:18J-25J.
3. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992; 33:1569-78.
4. Bischoff H, Angerbauer R, Bender J et al. Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis. 1997; 135:119-30.
5. Yee HS, Fong NT. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Ann Pharmacother. 1998; 32:1030-43.
6. Bradford RH, Shear CL, Chremos AN et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. Arch Intern Med. 1991; 151:43-9.
7. Jones P, Kafonek S, Laurora I et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998; 81:582-7.
8. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-9.
9. Pogson GW, Kindred LH, Carper BG. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol. 1999; 83:1146.
10. Cerivastatin for hypercholesterolemia. Med Lett. 1998; 40(Jan 16):13-4.
11. Bradford RH, Shear CL, Chromos AN et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. Am J Med. 1991; 91(suppl 1B):18S-24S.
12. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin/gemfibrozil combination therapy. JAMA 1990; 264:71-5.
13. Chichmanian RM, Mignot G, Spreux A. Rhabdomyolysis medicamentensis. Ann Med Interne (Paris). 1991; 142:587-91.
14. Davignon J, Hanefeld M, Nakaya N et al. Clinical efficacy and safety of cerivastatin: summary of pivotal Phase IIb/III studies. Am J Cordiol. 1998; 82:32J-9J.
15. Bakker-Arkema RG, Best J, Fayyad R et al. A brief review paper of the efficacy and safety of atorvastatin in early clinical trials. Atherosclerosis. 1997; 131:17-23.
16. Ellen RLB, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol. 1998; 81(4A):60B-4B.
17. Farnier M and the Cerivastatin Study Group. Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. Am J Cardiol. 1998; 82:47J-51J.
18. Mevacor package insert. West Point, PA: Merck; 1997 Mar.
19. Pravachol package insert. Princeton, NJ: Bristol-Myers Squibb; 1997 Apr.
20. Zocor package insert. West Point, PA: Merck; 1996 Dec.
21. Lescol package insert. Summit, NJ: Novartis Consumer Health; 1996 Nov.
22. Baycol package insert. West Haven, CT: Bayer; 1997.
23. Lipitor package insert. Morris Plains, NJ: Parke-Davis; 1997 Jan.
24. Marais GE, Larson KK. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann Intern Med. 1990; 112:228-30.
25. Lilja JJ, Kivisto KT,Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther. 1998; 64:477-83.
26. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med. 1998; 158:577-84.
27. Grundy SM. Consensus statement: role of therapy with "statins" in patients with hypertriglyceridemia. Am J Cardiol. 1998; 81 (4A):1B-6B.